Iain Fraser
About Iain Fraser
Iain Fraser serves as the Interim Chief Medical Officer at Fulcrum Therapeutics, a position he has held since 2023. He has extensive experience in the medical field, having worked in various roles at notable organizations including Abide Therapeutics, AlloVir, and Merck.
Current Role at Fulcrum Therapeutics
Iain Fraser serves as the Interim Chief Medical Officer at Fulcrum Therapeutics, a position he has held since 2023. His role is based in Cambridge, Massachusetts, and operates in a hybrid work environment. In this capacity, he is responsible for overseeing clinical strategies and medical affairs within the organization.
Previous Experience at Abide Therapeutics
Fraser worked at Abide Therapeutics in various capacities. He served as Executive Director for one year from 2014 to 2015 in Princeton, NJ. Following this, he held the position of Vice President from 2015 to 2019, contributing to the company's clinical development and strategic initiatives over a four-year period.
Clinical Leadership at AlloVir
From 2019 to 2022, Iain Fraser was the Vice President, Clinical Fellow at AlloVir, an ElevateBio Company. His tenure in the Greater Boston Area lasted for three years, where he played a significant role in advancing clinical programs and research in the field of infectious diseases.
Educational Background
Iain Fraser has an extensive educational background in medicine and science. He studied at the University of Cape Town, where he earned a Bachelor of Medicine (MBChB) from 1982 to 1987 and a Bachelor of Science (Hons) in Biochemistry from 1988 to 1989. He furthered his studies at the University of Oxford, obtaining a Doctor of Philosophy (DPhil) in Pathology/Experimental Pathology from 1989 to 1994. Additionally, he completed a Master of Science in Clinical Investigation at Harvard University from 2000 to 2002.
Experience at Massachusetts General Hospital
Iain Fraser worked at Massachusetts General Hospital as an Assistant in Pediatrics specializing in Infectious Diseases from 2000 to 2007. His seven-year tenure in the Greater Boston Area involved clinical responsibilities and contributions to pediatric infectious disease research.